ClinicalTrials.gg
TerminatedNCT03884465Updated Sep 13, 2021

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

A Phase 2 interventional study of Inhaled dry powder treprostinil (LIQ861) in Pulmonary Arterial Hypertension, sponsored by Liquidia Technologies, Inc.. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-13.

Sponsored by Liquidia Technologies, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
COVID

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
32nd of 44
15 · median 32
Started
2019
with 4 others
Phase 2
7 of 44
1 open now
Registered
35th of 44
by date
Lead sponsor
4 of 44
Liquidia Technologies, Inc.

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 32nd largest by enrollment, is one of 5 that started in 2019, is one of 7 in phase 2, and was the 35th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.

Read the detailed description

Data will be collected on acute and chronic hemodynamic response to inhaled dry powder treprostinil (LIQ861) via right-heart catheterization. Study subjects will contribute to the overall safety profile of LIQ861.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary arterial hypertension
  • Pulmonary hypertension
  • PAH
  • PH
  • WHO Group 1 pulmonary arterial hypertension
  • WHO Group 1 pulmonary hypertension
  • WHO Group 1 PAH
  • WHO Group 1 PH
  • WHO Group 1
  • Group 1 PAH
  • Group 1 PH
  • Idiopathic PAH
  • Heritable PAH
  • Drug induced PAH
  • Toxin induced PAH
  • Pulmonary shunt
  • Idiopathic pulmonary arterial hypertension
  • Heritable pulmonary arterial hypertension
  • Drug induced pulmonary arterial hypertension
  • Toxin induced pulmonary arterial hypertension
  • Connective tissue disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (A subject will be eligible for inclusion in this study only if all of the following criteria are met):

  1. An Institutional Review Board (IRB) approved is signed and dated by the subject prior to any study related activities.
  2. The subject is 18 years of age or older.
  3. If the subject is a female of , then the subject has a negative pregnancy test at the Day 1 Visit (tests performed within 2 days before Day 1 are accepted) and agrees to practice a highly effective (failure rate of less than 1% per year when used consistently and correctly) method of until 24 hours after completion of all study assessments defined in Appendix 1. If the subject is or has documented surgical sterilization, a pregnancy test and birth control is not necessary. It is the Investigator's responsibility for determining whether the subject has adequate birth control for study participation.
  4. The subject has been diagnosed with PAH belonging to one of the following subgroups of the updated Nice Clinical Classification Group 1, which includes:

    1. Idiopathic PAH (1.1), or
    2. Heritable PAH (1.2), or
    3. Drug and toxin induced PAH (1.3), or
    4. PAH associated with connective tissue disease (1.4.1), infection (1.4.2), or congenital heart disease (1.4.4) with simple systemic-to-pulmonary shunt at least 1 year after surgical repair
  5. The subject is Functional Class II - IV at Screening and:

    1. has not previously been treated for PAH, or
    2. has documented stable doses of no more than 2 approved non prostacyclin PAH-disease specific therapies for at least 3 months prior to Screening, is willing and able to add LIQ861 to their treatment regimen and is willing to hold the dosing of these therapies for at least 12 hours prior to study-mandated right heart catheterization procedures.
  6. The subject can complete a baseline six-minute walk distance (6MWD) ≥150 m.
  7. The subject has had evidence of (FEV1) and Forced Vital Capacity (FVC) ≥60% of predicted values and FEV1/FVC ratio ≥60% during the 6 month period prior to consent.

Exclusion Criteria (A subject is not eligible for inclusion in the study if any of the following criteria apply):

  1. The subject's clinical condition is such that, in the opinion of the Investigator, they are not expected to remain clinically stable for the duration of the study.
  2. Subjects with pulmonary hypertension (PH) in the Updated Nice Classification Groups 2-5, or PAH Group 1 subgroups not covered by the inclusion criteria (e.g., associated with portal hypertension [1.4.3] or with schistosomiasis [1.4.5]).
  3. The subject is currently taking prostacyclin analogues or agonists, including treprostinil, iloprost, epoprostenol or selexipag.
  4. The subject has discontinued any medication (except for anticoagulants, but otherwise including but not limited to oxygen, a different class of vasodilator, diuretic, digoxin, and digitalis) for pulmonary hypertension within 14 days prior to Day 1.
  5. The subject has had a new type of therapy (including but not limited to oxygen, a different class of vasodilator, diuretic, digoxin, and digitalis) for pulmonary hypertension added within 30 days prior to Day 1.
  6. The subject has uncontrolled systemic hypertension as evidenced by systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg at the time of screening.
  7. The subject has a history of hemodynamically significant left-sided heart disease including, but not limited to: aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, or symptomatic coronary artery disease (CAD).
  8. The subject has had an atrial septostomy.
  9. The subject has a history of prolongation of on as follows: Male subjects with a corrected QT interval using Fridericia's formula (QTcF) >450 msec and female subjects with QTcF >470 msec.
  10. The subject has any serious or life-threatening disease other than conditions associated with PAH.
  11. The subject is taking any excluded medications listed in the Investigator's Brochure, namely inhibitors and inducers of CYP2C8 (see Appendix 3).
  12. The subject has a or allergy to any of the ingredients of LIQ861, NO, or other allergies (clinical relevance per Investigator judgment).
  13. The subject has had an acute pulmonary embolus within 6 months prior to Baseline.
  14. The subject has had a stroke or within 6 months prior to Baseline.
  15. The subject has evidence of an active uncontrolled sepsis or systemic infection in the period after informed consent up to Baseline.
  16. The subject is pregnant or lactating.
  17. The subject has any musculoskeletal disease or any other disease that limits evaluation of 6MWD.
  18. The subject has participated in an product or device study within the 30 days prior to Baseline.
  19. The subject has current evidence of drug abuse in the opinion of the Investigator.
  20. The subject has severe hepatic impairment as evidenced by any history of ascites AND encephalopathy.
  21. The subject has severe renal impairment (estimated [eGFR] \<35 mL/min utilizing the Modification of Diet in Renal Disease (MDRD) study equation or requires dialytic support.
  22. The subject is an employee or an immediate family member to an employee of the Sponsor or the Investigator.
  23. The subject is not a member or beneficiary of a social security scheme.
  24. The subject lacks a legal protection measure.
  25. The subject has been deprived of their liberty by a judicial or administrative decision.
  26. The subject has a known or infection with active viral replication.
  27. The subject has a known HIV infection with less than 200 and more than undetectable viral load, defined as less than 50 copies /mL.
  28. The subject required use of intravenous inotropes including, but not limited to, Levosimendan, Dopamine, Dobutamine, Dopexamine, Epinephrine, Isoprenaline (isoproterenol), Norepinephrine (noradrenaline), Milrinone, or Amrinone, within 30 days prior to Baseline.
  29. The subject required intravenous diuretic therapy within 30 days prior to Baseline.
  30. Subjects taking vitamin K antagonist therapy with a known ≥3.5 (assessed per local care standards) at the time of screening assessments or at Baseline.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Inhaled dry powder treprostinil (LIQ861)

    Full study population receives inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg or 100μg capsule strengths.

    Drug: Inhaled dry powder treprostinil (LIQ861)

Interventions

  • Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.

    Also known as: Inhaled treprostinil, Inhaled prostacyclin

06

What researchers measure

Primary outcomes

  1. Change in Pulmonary Vascular Resistance (PVR)

    Calculated in Wood units

    Time frame: 2 hours (120 minutes) post-dose on Day 1 and Week 16

  2. Change in Pulmonary Artery Pressure (PAP)

    Systolic, diastolic, and mean pressure measured in millimeters of mercury (mmHG)

    Time frame: 2 hours (120 minutes) post-dose on Day 1 and Week 16

  3. Change in Cardiac Output (CO)

    Measured in liters per minute (L/min)

    Time frame: 2 hours (120 minutes) post-dose on Day 1 and Week 16

  4. Change in Pulmonary Artery Oxygen Saturation (PAO2%)

    Measured as a percent oxyhemoglobin saturation

    Time frame: 2 hours (120 minutes) post-dose on Day 1 and Week 16

Secondary outcomes

  1. Number of participants with treatment emergent adverse events (AEs)

    Treatment-emergent adverse events and serious adverse events will be grouped by MedDRA System Organ Class, dose level at onset, time on drug at onset, and relationship to dose titration.

    Time frame: Baseline until the end of study, approximately 18 months (Mar-2021)

07

Study locations

3 sites
  • CHRU de Nancy
    Nancy, Vandoeuvre Les Nancy 54500, France
  • CHU de Bicetre
    Le Kremlin-Bicêtre, 94270, France
  • Studienambulanz fur Pulmonale Hypertonie at Medizinishe Klinik II, Universitatskinikum Giessen und Marburg GmbH
    Gießen, 35392, Germany
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Dec 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2019
First posted
Mar 21, 2019
StartActual
Nov 11, 2019
Primary completionActual
Dec 23, 2020
CompletionActual
Dec 23, 2020
Last update
Sep 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03884465
Lead sponsor
Liquidia Technologies, Inc.
Collaborators
FGK Clinical Research GmbH
Responsible party
Sponsor
First posted
Mar 21, 2019
Start date
Nov 11, 2019
Primary completion
Dec 23, 2020
Completion
Dec 23, 2020
Last update
Sep 13, 2021

Study contacts

Ardeschir Ghofrani, Prof. MD.
principal investigator · Universitatskinikum Giessen und Marburg GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion